359 related articles for article (PubMed ID: 36111299)
1. GPCR heteromers: An overview of their classification, function and physiological relevance.
Dale NC; Johnstone EKM; Pfleger KDG
Front Endocrinol (Lausanne); 2022; 13():931573. PubMed ID: 36111299
[TBL] [Abstract][Full Text] [Related]
2. Arrestin recruitment and signaling by G protein-coupled receptor heteromers.
Mores KL; Cassell RJ; van Rijn RM
Neuropharmacology; 2019 Jul; 152():15-21. PubMed ID: 30419245
[TBL] [Abstract][Full Text] [Related]
3. Application of G protein-coupled receptor-heteromer identification technology to monitor β-arrestin recruitment to G protein-coupled receptor heteromers.
See HB; Seeber RM; Kocan M; Eidne KA; Pfleger KD
Assay Drug Dev Technol; 2011 Feb; 9(1):21-30. PubMed ID: 21133678
[TBL] [Abstract][Full Text] [Related]
4. Exploring a role for heteromerization in GPCR signalling specificity.
Rozenfeld R; Devi LA
Biochem J; 2011 Jan; 433(1):11-8. PubMed ID: 21158738
[TBL] [Abstract][Full Text] [Related]
5. G protein-coupled receptor oligomerization revisited: functional and pharmacological perspectives.
Ferré S; Casadó V; Devi LA; Filizola M; Jockers R; Lohse MJ; Milligan G; Pin JP; Guitart X
Pharmacol Rev; 2014; 66(2):413-34. PubMed ID: 24515647
[TBL] [Abstract][Full Text] [Related]
6. G-protein-coupled receptor type A heteromers as an emerging therapeutic target.
Guidolin D; Agnati LF; Marcoli M; Borroto-Escuela DO; Fuxe K
Expert Opin Ther Targets; 2015 Feb; 19(2):265-83. PubMed ID: 25381716
[TBL] [Abstract][Full Text] [Related]
7. GPCR homomers and heteromers: a better choice as targets for drug development than GPCR monomers?
Casadó V; Cortés A; Mallol J; Pérez-Capote K; Ferré S; Lluis C; Franco R; Canela EI
Pharmacol Ther; 2009 Nov; 124(2):248-57. PubMed ID: 19664655
[TBL] [Abstract][Full Text] [Related]
8. Neuroprotection afforded by targeting G protein-coupled receptors in heteromers and by heteromer-selective drugs.
Franco R; Navarro G
Front Pharmacol; 2023; 14():1222158. PubMed ID: 37521478
[TBL] [Abstract][Full Text] [Related]
9. G protein-coupled receptor heteromer identification technology: identification and profiling of GPCR heteromers.
Mustafa S; Pfleger KD
J Lab Autom; 2011 Aug; 16(4):285-91. PubMed ID: 21764024
[TBL] [Abstract][Full Text] [Related]
10. Revolution in GPCR signalling: opioid receptor heteromers as novel therapeutic targets: IUPHAR review 10.
Fujita W; Gomes I; Devi LA
Br J Pharmacol; 2014 Sep; 171(18):4155-76. PubMed ID: 24916280
[TBL] [Abstract][Full Text] [Related]
11. Oligomerization of GPCRs involved in endocrine regulation.
Kleinau G; Müller A; Biebermann H
J Mol Endocrinol; 2016 Jul; 57(1):R59-80. PubMed ID: 27151573
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological targeting of G protein-coupled receptor heteromers.
Moreno E; Casajuana-Martin N; Coyle M; Campos BC; Galaj E; Del Torrent CL; Seyedian A; Rea W; Cai NS; Bonifazi A; Florán B; Xi ZX; Guitart X; Casadó V; Newman AH; Bishop C; Pardo L; Ferré S
Pharmacol Res; 2022 Nov; 185():106476. PubMed ID: 36182040
[TBL] [Abstract][Full Text] [Related]
13. Heteromers of μ-δ opioid receptors: new pharmacology and novel therapeutic possibilities.
Fujita W; Gomes I; Devi LA
Br J Pharmacol; 2015 Jan; 172(2):375-87. PubMed ID: 24571499
[TBL] [Abstract][Full Text] [Related]
14. Screening β-arrestin recruitment for the identification of natural ligands for orphan G-protein-coupled receptors.
Southern C; Cook JM; Neetoo-Isseljee Z; Taylor DL; Kettleborough CA; Merritt A; Bassoni DL; Raab WJ; Quinn E; Wehrman TS; Davenport AP; Brown AJ; Green A; Wigglesworth MJ; Rees S
J Biomol Screen; 2013 Jun; 18(5):599-609. PubMed ID: 23396314
[TBL] [Abstract][Full Text] [Related]
15. β-arrestins and G protein-coupled receptor trafficking.
Tian X; Kang DS; Benovic JL
Handb Exp Pharmacol; 2014; 219():173-86. PubMed ID: 24292830
[TBL] [Abstract][Full Text] [Related]
16. β-arrestin signalling and bias in hormone-responsive GPCRs.
Reiter E; Ayoub MA; Pellissier LP; Landomiel F; Musnier A; Tréfier A; Gandia J; De Pascali F; Tahir S; Yvinec R; Bruneau G; Poupon A; Crépieux P
Mol Cell Endocrinol; 2017 Jul; 449():28-41. PubMed ID: 28174117
[TBL] [Abstract][Full Text] [Related]
17. GPCR systems pharmacology: a different perspective on the development of biased therapeutics.
Eiger DS; Pham U; Gardner J; Hicks C; Rajagopal S
Am J Physiol Cell Physiol; 2022 May; 322(5):C887-C895. PubMed ID: 35196164
[TBL] [Abstract][Full Text] [Related]
18. Understanding the role of heteroreceptor complexes in the central nervous system.
Fuxe K; Borroto-Escuela D; Fisone G; Agnati LF; Tanganelli S
Curr Protein Pept Sci; 2014; 15(7):647. PubMed ID: 25256022
[TBL] [Abstract][Full Text] [Related]
19. Biased signalling: from simple switches to allosteric microprocessors.
Smith JS; Lefkowitz RJ; Rajagopal S
Nat Rev Drug Discov; 2018 Apr; 17(4):243-260. PubMed ID: 29302067
[TBL] [Abstract][Full Text] [Related]
20. Allosteric coupling and biased agonism in G protein-coupled receptors.
Bock A; Bermudez M
FEBS J; 2021 Apr; 288(8):2513-2528. PubMed ID: 33621418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
